Engagement Manager Solutions

JEFFREY T. O’NEIL, MS

Greater Miami, FL 786-***-**** ********@*****.*** linkedin.com/in/jeffoneilmiami STAKEHOLDER ENGAGEMENT, THOUGHT LEADER LIAISON

New Business Development Physician Advocacy Relations Biotech and Pharmaceutical Industries Top performing, award winning leader with experience in the areas of Business Transformation Development, Emerging Markets, Leadership and Sales, earned a reputation for being a team leader and unifier while also being able to deliver on sales results, by identifying and capturing market opportunities to drive growth. Characterized as possessing a passion for garnering and developing physician advocacy by working to establish lasting relationships with a multitude of International and National Key Opinion Leaders in various rare disease state product launches.

KEY ATTRIBUTES

• Fluent in Spanish with a working knowledge of Portuguese, has allowed me the ability to work in Spain, Brazil and the US Territory of Puerto Rico.

• Master’s degree in Sports Medicine and has worked with various professional, international and college sports teams in his previous career as an Athletic Trainer. PROFESSIONAL EXPERIENCE TAKEDA PHARMACEUTICALS, Cambridge, MA November 2019 - Present SENIOR THOUGHT LEADER LIAISON (FL, GA, AL, MS, LA, MI, IN, TN, NC, SC, VA, PR) Profiled, developed, and maintained relationships with key thought leaders in the Inflammatory Bowel Disease and Eosinophilic Esophagitis space, successfully lining up advocates in gastroenterology, and immunology who spoke to the efficacy and benefits of Takeda’s GI products during conferences, individual meetings, and thought leader interactions

• Aligned with cross functional teammates, to appropriately deploy resources, like Takeda Leadership engagement with top tier KOL’S, as determined by brand and portfolio teams through influence and Centers of Excellence, top HTC, and community-based practices

• Executed Takeda’s IBD and EOE strategy for non-sales KOL engagement activities

• Developed a regional KOL engagement strategy by identifying, profiling, cultivating, maintaining long-term relationships with KOL’S

• Appropriately gathered market intelligence and information to support overall business strategy

• Served as a resource for all commercial teams and Matrix partners regarding KOL landscape and expertise within the IBD community

• Partnered with the marketing team to help identify, recommend, and build Advisory Boards

• Collaborated with marketing for the compliant selection and nomination of speakers for peer-to-peer programs, symposia, and product theaters

• Trained and onboarded both new and existing KOL speakers using approved decks and materials

• Lead for ACCELERATE, an internal mentorship program for individuals interested in pursuing the TLL Role

• Directed Congress planning regionally and nationally for all major IBD meetings

• IMPACTO Takeda Resource Group Lead for GI Business Unit and point of contact to resolve KOL issues SANOFI-GENZYME, INC. Cambridge, MA March 2018 - November 2019 THOUGHT LEADER LIAISON, EMERGING MARKETS: (FL, GA, AL, MS, LA, AR, OK, IL, MI, IN, KS, MO, TN, NC, SC, PR) Profiled, developed, and maintained relationships with over 35 key thought leaders in Rare Bleeding Disorders successfully lining up advocates in Hematology and Oncology, who spoke to the efficacy and benefits of Sanofi-Genzyme’s Rare Bleeding Disorders products during conferences, individual meetings, and thought leader interactions.

• Educated Thought Leaders to understand disease mechanisms and role of products in the management of Hemophilia using on-label and PRC-approved materials; successfully built advocacy for treatment.

• Managed and trained contracted speakers on approved medical education content, ensuring accurate and effective presentations of products, including specific messages relating to compliance. JEFFREY T. O’NEIL MS PAGE 2

• Collaborated with Brand and Marketing Teams in the US, Taiwan, and Colombia to develop, refine and execute engagement strategy, along with co-creating strategies with cross-functional partners.

• Partnered with the marketing team to build Advisory Boards: identified, recommended, and invited potential advisors, moderators, and speakers.

• Led Congress planning regionally and nationally for all major Rare Blood Disorders (ASH, WFH, ISTH, NHF).

• Collaborated with Thought Leaders to bring relevant on-label and PRC-approved information and to solicit input to be considered in the development of strategies.

• As the TLL Lead, engaged and collaborated with our Marketing partners to develop strategic marketing plans based on Fact Finding Questions (FFQ’s) and insights gathered by the TLL Team.

• Partnered with the Director of Emerging Markets for Rare Blood Disorders to develop KOL development and marketing plans for the countries in Latin America and Taiwan GENENTECH, INC. South San Francisco, CA January 2015 - March 2018 THOUGHT LEADER LIAISON (FL, AL, MS, LA, AR, PR)

Identified, profiled, developed, and maintained relationships with over 20 key thought leaders in Idiopathic Pulmonary Fibrosis (IPF) lining up advocates in Pulmonology and Rare Disease, who spoke to the efficacy and benefits of Esbriet (Pirfenidone) during conferences, individual meetings, and thought leader interactions.

• Educated Thought Leaders to understand disease mechanisms and the potential role of products in the management of IPF using on-label and PRC-approved materials; successfully built advocacy for treatment.

• Managed and trained 15 contracted speakers on approved medical education content, ensuring accurate and effective presentations of products, including specific messages relating to compliance.

• Collaborated with Brand and Marketing Teams to develop, refine and execute engagement strategy, and co-created strategies with cross-functional partners.

• Partnered with the marketing team to build 5 Advisory Boards: identified, recommended, and invited potential advisors, moderators, and speakers.

• Led Congress planning regionally and nationally with marketing and TLL colleagues.

• Collaborated with Thought Leaders to bring relevant on-label and PRC-approved information and to solicit input to be considered in the development of strategies. THE MEDICINES COMPANY, Parsippany, NJ September 2006 - January 2015 Southeast US and Puerto Rico

Engagement Partner (Regional Sales Manager) March 2013 - January 2015

• Led each team member to successfully achieve 100% to plan for Q1, 2014.

• Led Book of Business for Angiomax that covered 4 states and the island of Puerto Rico, including 14 Engagement Managers generating sales more than $80 MM.

• Established close alignment with partners, AstraZeneca, and Boston Scientific (BSCI) sales and management, to establish goals on focused accounts, which resulted in enhanced sales and revenue.

• Team led growth for BSCI Partnership, with an increase of $490K for Q2 2014.

• Managed and implemented contracts for hospitals and systems in the U.S. mainland and Puerto Rico.

• Recruited and hired Customer Solutions Manager and Infectious Disease Solutions Expert positions.

• Directed daily business operations of Team Kaizen, consisting in education, goal setting, interviewing, and hiring for the Book of Business.

Engagement Manager September 2006 - December 2013 Sold ANGIOMAX a Direct Thrombin Inhibitor to Interventional Cardiologists and the Cardiac Catheterization Laboratories in Miami and Puerto Rico. Directed sales and marketing of CLEVIPREX, a Dihydropyridine Calcium Channel Blocker for use in Cardio-Thoracic Surgery, Neurosurgery, Vascular Surgery, Intensive Care Units and Emergency Rooms.

• 2013 Rank: Top 10% of Engagement Managers.

• President’s Award 2011 and 2012 (Top 10% nationally)

• Sales Excellence Award 2008 (Top 20% nationally)

• MVP South Florida Region 2008

• Regional Director’s Award 2007 for work accomplished on the island of Puerto Rico. JEFFREY T. O’NEIL MS PAGE 3

• Launched Angiomax; successfully acquired formulary approval in all major institutions on the island of Puerto Rico.

• Led Angiomax education for our partner Grupo Ferrer in Barcelona and Madrid, Spain, as well as Miami.

• Initiated Engagement Manager (EM) Advisory Board along with EM Compensation Team.

• Business intelligence Lead for hospitals and KOL’s in the country of Brazil, along with educating Business Manager on Angiomax and Cleviprex.

ADDITIONAL EXPERIENCE

ORTHO BIOTECH (A JOHNSON AND JOHNSON COMPANY) Senior Product Specialist Promoted sales and marketing of Procrit, an Injectable Recombinant Biologic Red Blood Cell Growth Factor to Internal Medicine Physicians, Rheumatologists and Endocrinologists in the Dade County area.

• Presidents Cup Winner for 2005

• Ranked No. 28 out of 293 representatives in the Nation.

• Member of the Ortho-Biotech Advisory Board.

• Fast tracked to management training, within 5 months of joining the company. JANSSEN PHARMACEUTICA (A JOHNSON & JOHNSON COMPANY) Professional Sales Representative Handled the sales and marketing of Aciphex a Proton Pump Inhibitor to Gastroenterologists and Internal Medicine Physicians in the territory of Dade and Broward County.

• Ranked number 1 in sales in Miami District for 1st and 2nd Quarter for 2004-2005.

• Ranked number 2 in Southeast Region in sales for 1st and 2nd Quarter for 2004-2005.

• District Rookie Representative of the Year.

EDUCATION Master of Science Degree (MS), Sports Medicine, University Of Miami - Coral Gables, FL Bachelor of Science Degree (BS), Education. Minor, Spanish, Florida State University, Tallahassee, FL LANGUAGES English, Spanish, Portuguese

Contact this candidate